Dockeray C J, Sheppard B L, Bonnar J
Trinity College Department of Obstetrics and Gynaecology, Sir Patrick Dun Research Laboratory, St James's Hospital, Dublin, Ireland.
Br J Obstet Gynaecol. 1989 Jul;96(7):840-4. doi: 10.1111/j.1471-0528.1989.tb03325.x.
Forty women with established menorrhagia were treated with either mefenamic acid (500 mg thrice daily for 3-5 days in two cycles) or danazol (100 mg twice daily for 60 days) in an open parallel group randomized study. Mefenamic acid reduced mean menstrual blood loss from 160 ml to 127 ml (20%, P less than 0.01). Danazol reduced mean menstrual loss from 163 ml to 65 ml (60%, P less than 0.001). The percentage reduction in menstrual blood loss was significantly greater in the danazol group than in the mefenamic acid group, but the adverse side-effects occurred significantly more often in the danazol group (75%) than in the mefenamic acid group (30%, P less than 0.005). Overall, approximately half the women in each group were prepared to continue with the treatment they received to reduce their menstrual bleeding.
在一项开放性平行组随机研究中,对40名确诊为月经过多的女性,分别给予甲芬那酸(500毫克,每日3次,两个周期,每个周期服用3 - 5天)或达那唑(100毫克,每日2次,服用60天)进行治疗。甲芬那酸使平均月经失血量从160毫升降至127毫升(减少20%,P<0.01)。达那唑使平均月经失血量从163毫升降至65毫升(减少60%,P<0.001)。达那唑组月经失血量减少的百分比显著高于甲芬那酸组,但达那唑组出现不良反应的频率显著高于甲芬那酸组(75% 对比30%,P<0.005)。总体而言,每组中约有一半的女性愿意继续接受她们所接受的治疗以减少月经出血。